• Triacetin Workflows for Cell and Metabolic Research

  2026-09-17

  Triacetin, or glyceryl triacetate, supports distinct glioblastoma, metabolic, ocular-formulation, and lipid-focused workflows. This practical guide separates reported biological activity from formulation utility, with concentration selection, controls, and troubleshooting steps for reproducible assays.

• Cepharanthine in Endometriosis: Organoid & In Vivo

  2026-09-17

  A 2026 study evaluates the biscoclaurine alkaloid Cepharanthine across immortalized stromal cells, patient-derived endometrial organoids, and a murine peritoneal endometriosis model. Its findings connect lesion-growth suppression with G0/G1 arrest, DNA damage, impaired repair, and mitochondrial apoptosis, while also illustrating how organoids can improve preclinical treatment evaluation.

• CBD, FAAH, and Orofacial Inflammatory Pain

  2026-09-16

  This 2026 mouse study shows that cannabidiol (CBD) can reduce both inflammatory orofacial nociception and pain-associated affective and cognitive deficits. By combining behavioral, biochemical, endocannabinoid, and circuit-level analyses, the work links peripheral CB2-associated signaling, central CB1-associated anandamide regulation, and altered serotonin dynamics in the central amygdala.

• Iptacopan Monotherapy in PNH: Evidence and Methods

  2026-09-16

  This phase 2 proof-of-concept study evaluated oral Iptacopan (LNP023) as single-agent factor B inhibition in treatment-naive patients with active paroxysmal nocturnal hemoglobinuria. Rapid reductions in LDH and other hemolytic markers, together with improved hemoglobin and reduced transfusion requirements, support proximal alternative-pathway inhibition as a clinically relevant strategy, while the small open-label design limits generalization.

• Capsaicin: From TRPV1 Signaling to KDM1A

  2026-09-15

  Capsaicin is more than a canonical sensory-neuron agonist. Its rapid TRPV1 ion channel activation and reversible KDM1A/LSD1 inhibition create a translational framework linking pain, inflammation, itch, and gastric cancer research—provided that investigators separate exposure, target engagement, and phenotype.

• HyperScript™ Reverse Transcriptase for RPE RNA

  2026-09-15

  Learn how HyperScript™ Reverse Transcriptase can support RNA to cDNA conversion when RPE/choroid samples contain low-abundance transcripts or structured RNA. This workflow-focused guide connects microbiome-associated retinal transcriptomics with practical qPCR validation, control design, and troubleshooting.

• Dynasore: Dynamin GTPase Inhibitor Guide

  2026-09-14

  Dynasore is a reversible, cell-permeable dynamin GTPase inhibitor used to dissect dynamin-dependent endocytosis and membrane trafficking. Its approximately 15 µM biochemical IC50 is a benchmark rather than a universal cellular dose, so assay-specific controls and orthogonal validation are essential.

• ARCA Cy5 EGFP mRNA in Macrophage Assays

  2026-09-14

  ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to distinguish macrophage uptake from productive translation in mRNA delivery studies. This article develops an assay framework for connecting nanoparticle design, intracellular trafficking, and expression outcomes.

• D-N-Acetylgalactosamine: Protocol and QC Guide

  2026-09-13

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein composition studies, brain heteropolysaccharides analysis, and related glycosylation pathway workflows. It is appropriate for aqueous or validated DMSO preparations, but not for ethanol-based protocols or long-term storage of prepared solutions.

• MK-5108 (VX-689) Aurora A Workflow

  2026-09-12

  MK-5108, also known as VX-689, gives researchers a highly selective way to interrogate Aurora A-dependent cell-cycle control across cancer cell line proliferation assays and xenograft studies. This practical guide connects assay design with recent retinoblastoma evidence, emphasizing solvent handling, selectivity controls, response timing, and reproducible translational workflows.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X)

  2026-09-11

  Phosphatase Inhibitor Cocktail (2 Tubes, 100X) helps limit endogenous phosphatase activity during sample preparation so phosphorylation-dependent signals can be measured more consistently. It is intended for research workflows such as immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry, but it is not a diagnostic or medical reagent.

• H-89 as a Mechanistic Lever in Wnt Bone Biology

  2026-09-11

  H-89 offers translational researchers a practical way to test whether PKA activity connects Wnt stimulation with O-GlcNAcylation, glycolytic rewiring, and osteoblast function. By combining pharmacology with time-resolved metabolic and genetic validation, researchers can turn a pathway inhibitor into a disciplined mechanistic decision tool.

• PP 2 (AG 1879): Reliable Src Assay Design

  2026-09-10

  A scenario-based guide to using PP 2 (AG 1879), SKU A8216, in viability, proliferation, invasion, immune-signaling, and vascular assays. It connects documented Src-family potency and solubility with practical controls, interpretation limits, and vendor-selection criteria.

• DMG-PEG2000-NH2 for Reliable Cell Assays

  2026-09-10

  This scenario-driven guide explains how DMG-PEG2000-NH2 (SKU M2006) can support reproducible linker, liposome, and lipid nanoparticle workflows without confusing formulation effects with direct cytotoxicity. It combines product specifications with evidence from sulfonamide optimization research to guide practical assay design and interpretation.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-09-09

  Pair direct Cy5 tracking with Firefly luciferase expression to distinguish mRNA uptake from productive translation. This workflow combines delivery optimization, translation efficiency assay design, and corona-aware troubleshooting in one dual-readout platform.

8041 records 1/537 page Next 12345 下5页 Last page